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Abstract
Background: Human osteopontin (OPN), a known tumor associated protein, exists in different isoforms, whose function is
unclear. It also possesses a RGD domain, which has been implicated in diverse function. Here, we use genetic approaches to
systematically investigate the function of the RGD domain in different OPN isoforms on tumor progression and metastasis
for 2 different solid tumor models.
Methodology/Principal Findings: Using isoform-specific qRT-PCR, we found that OPN-A and B were the main isoforms
overexpressed in evaluated human tumors, which included 4 soft tissue sarcomas, 24 lung and 30 head and neck
carcinomas. Overexpression of either OPN-A or B in two different cell types promoted local tumor growth and lung
metastasis in SCID mouse xenografts. However, expression of either isoform with the RGD domain either mutated or
deleted decreased tumor growth and metastasis, and resulted in increased apoptosis by TUNEL staining. In vitro, whereas
mutation of the RGD domain did not affect cell-cell adhesion, soft agar growth or cell migration, it increased apoptosis
under hypoxia and serum starvation. This effect could be mitigated when the RGD mutant cells were treated with condition
media containing WT OPN. Mechanistically, the RGD region of OPN inhibited apoptosis by inducing NF-kB activation and
FAK phosphorylation. Inhibition of NF-kB (by siRNA to the p65 subunit) or FAK activation (by a inhibitor) significantly
increased apoptosis under hypoxia in WT OPN cells, but not in RGD mutant cells.
Conclusion/Significance: Unlike prior reports, our data suggest that the RGD domain of both OPN-A and B promote tumor
growth and metastasis mainly by protecting cells against apoptosis under stressed conditions and not via migration or
invasion. Future inhibitors directed against OPN should target multiple isoforms and should inhibit cell survival mechanisms
that involve the RGD domain, FAK phosphorylation and NF-kB activation.
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Introduction
Osteopontin (OPN) is a phosphoglycoprotein that has impor-
tant physiological functions in bone remodeling [1], immune
response and inflammation [2,3]. It is also a tumor-associated
protein, which mediates tumor transformation and malignant
progression [4,5]. Elevated OPN levels have been shown to
correlate with increased tumor progression and poor survival in
many solid tumors [6]. OPN has been proposed to promote tumor
progression through several mechanisms, including increased cell
survival, migration, invasion, neovascularization, and modulation
of immune function [7].
When OPN was first identifieda n ds e q u e n c e df r o mar a t
osteosarcoma phage library, it was found to contain the RGD
sequence that is known to be present on fibronectin and binds to
integrins [8]. Therefore, it was hypothesized that the RGD
domain of OPN functionally mediates cell adhesion, migration
and invasion through integrin engagement. Further studies
confirmed these proposed functions of the OPN RGD domain
in osteoblasts, endothelial cells and certain cancer cell lines [5].
However, most of these studies employed recombinant OPN
(which lacks post-translational modifications), competing syn-
thetic RGDpeptides or their mutated versions, and avb3in te grin
blocking antibodies to investigate the role of the RGD domain
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9633[9,10,11,12,13]. Some studies used purified OPN derived from
non-cancer sources such as breast milk, bones, osteoblasts or
smooth muscle cells [14,15,16,17]. However, recent data have
shown that the pattern of OPN post-translational modification,
specifically phosphorylation, is cell-type dependent and may
affect the degree of cell adhesion to this molecule [4,18,19,20].
For example, OPN from ras-transformed mouse fibroblasts has
less phosphorylation than OPN from differentiated mouse
osteoblasts and can bind more readily to MDA435, a breast
cancer cell line [19]. Similarly, tumor derived OPN has been
shown to exist in a secreted form, not bound to the extracellular
matrix, and unable to support cell adhesion when added to the
condition media [21]. Therefore, the question of whether the
RGD domain of tumor-derived OPN indeed mediates cell
adhesion and migration has not been directly addressed. Only
one study has attempted to answer this question by overexpress-
i n gf u l l - l e n g t hO P N - Bs p l i c ef o r ma n dt h es a m ec o n s t r u c tw i t h
the RGD domain deleted in one breast cancer cell line [22]. This
study revealed that loss of the RGD region partially decreased
lymphatic metastasis in a breast cancer model, however, deletion
of the entire domain may result in unpredictable structural effects
that can interfere with function.
Another layer of added complexity is that human OPN gene is
subject to alternative splicing, which yields three distinct
isoforms: OPN-A (full-length transcript), OPN-B (lacks exon 5
or 14 amino acids) and OPN-C (lacks exon 4 or 28 amino acids)
[23]. The relative expression of the 3 isoforms in human tumors
and their function is not well characterized. While one study
suggested that OPN-C was selectively expressed in invasive
breast cancer and more likely to support anchorage independent
tumor growth than OPN-A [24], another study indicated that
OPN-C was less likely to promote cell migration and invasion
than the other 2 OPN isoforms in mesothelioma cells [25]. These
differences in OPN isoform expression have not consistently been
investigated.
To address the function of the RGD domain in tumor-derived
OPN for different splice forms and in the different human tumor
cell lines, we overexpressed (1) wild type OPN (WT), (2) OPN with
mutations in the RGD domain (RAA), or (3) OPN with the RGD
deleted (NoRGD) for the two different splice forms: OPN-A and
OPN-B. We have previous analyzed several primary human
cancers, including soft tissue sarcomas (STS), non-small cell lung
cancers (NSCLC) and head and neck squamous cell carcinomas
(HNSCC) and found that OPN-A and B but not C had elevated
expression in these tumors compared to matched normal tissues.
Overexpression of either the WT OPN-A or OPN-B isoform
resulted in enhanced tumor growth and metastatic lung colony
formation in two cell types. This effect appeared to be mediated
through the RGD segment since either mutation or deletion of this
domain abolished OPN-enhancement of tumor growth or
metastasis. Comparison of RGD-mutated and RGD-WT tumors
indicated that OPN-promotion of tumor growth was due to less
apoptosis in WT cells. In vitro studies showed that RGD mutation
did not affect cell adhesion, migration or invasion in these cell
lines. However, it increased cell apoptosis under hypoxia and
serum starvation when compared to WT OPN expressing cells,
and this effect was partly restored with condition media enriched
in WT OPN. OPN anti-apoptotic effect was signaled mainly
through the activation of FAK and NF-kB on further investiga-
tion. Taken together, these results suggest that the RGD domain
of tumor-derive OPN promotes tumor growth and metastasis
mainly through cell survival mechanisms, involving FAK and NF-
kB in our model.
Materials and Methods
Cell Lines & Hypoxia Treatment
MiaPaCa-2 (human pancreatic cancer cell line), HT1080
(human fibrosarcoma cell line), FaDu (human HNSCC cell line),
NCI-460 (human NSCLC cell line) and MDA231 (human breast
carcinoma cell line) were obtained from the American Type
Culture Collection (ATCC). SCC22B (human HNSCC cell line)
was obtained from the University of Michigan (Courtesy Dr.
Carey). Cell lines were maintained in DMEM supplemented with
10% fetal bovine serum. For hypoxia treatments, the cells were
maintained in an anoxia chamber (Sheldon Manufacturing,
Cornelius, OR) with an estimated pO2,0.02% for specified
durations.
Antibodies
The following antibodies were used: mouse monoclonal
antibodies against phospho-tyrosine 397 FAK, total FAK and
human Bcl-2 (BD Biosciences, San Jose, CA), mouse monoclonal
anti-XIAP antibody (Abcam, Cambridge, MA), mouse monoclo-
nal anti-b-actin antibody (Sigma-Aldrich, St Louis, MO), and
rabbit polyclonal antibodies against AKT and phospho-serine 473
AKT (Cell Signaling, Danvers, MA).
Construction of OPN Plasmids and Transfection
Human OPN constructs were cloned into pcDNA 3.1 vector
(Invitrogen, Carlsbad, CA). OPN-A was PCR amplified and OPN-
A-RAA was generated by site-directed mutagenesis. OPN-B and
OPN-B-NoRGD (RGD deleted) were gifts from Dr. Alison Allan
(Univ. of Western Ontario) [22]. HT1080 and MiaPaCa-2 cells
were transfected using Lipofectamine 2000 (Invitrogen).
Immunoblotting
Immunoblotting was performed as previously described [26].
Briefly, cells were lysed using 9 M urea and 75 mM Tris HCl
(pH 7.5) lysis buffer supplemented with 150 mM b-mercaptoeth-
anol. Equivalent amounts of protein were denatured, electropho-
resed, and transferred to membranes. After incubation/washing
with the appropriate primary and secondary antibodies, proteins
were detected by Amersham ECL (GE Healthcare) and autora-
diography film.
In Vitro Cell Proliferation, Adhesion, Soft Agar Growth,
Migration, Scratch and NF-kB Luciferase Reporter Assays
All assays below were performed in serum free media whenever
appropriate to ensure that no exogenous OPN was added. In vitro
cell proliferation was assessed by cell counts with a hemacytom-
eter. To assess in vitro cell adhesion, FaDu HNSCC cells expressing
different OPN constructs were plated in 24-well plates and
incubated overnight. Luciferase expressing FaDu cells were then
added to each well and allowed to adhere for 30 or 60 minutes.
After non-adherent cells were washed away, residual luciferase
activity was measured. Cell-cell adhesion, measured by residual
luciferase signal, was quantified as a percentage of the total
luciferase activity from input luciferase expressing FaDu cells [27].
For the soft agar colony formation assay, MiaPaCa-2 cells (5610
3),
overexpressing different OPN constructs, were plated on soft agar
and grown for 10-14 days followed by crystal violet staining. The
number of colonies/plate and colony size, expressed as average
area, were quantified using RT-Image software [28]. The scratch
assay was performed with MiaPaCa-2 cells, overexpressing various
constructs. Upon growth to confluency, cells were pipet scratched,
cultured in serum-free media and maintained in hypoxia for
OPN RGD Promotes Tumor Growth
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previously described [26].
Reverse Transcription Polymerase Chain Reaction
Analysis (RT-PCR)
RNA purification and RT-PCR was performed as previously
described [26]. The following oligomers were used for RT-PCR:
forward 59- TTGCTTTTGCCTCCTAGGCA-39 and reverse 59-
GTGAAAACTTCGGTTGCTGG-39.
OPN ELISA
OPN ELISAs were performed as previously described [30].
Tumor Growth and Metastasis
All animal studies were approved by the Stanford University
Administrative Panel on Laboratory Animal Care (APLAC).
HT1080 (2.5610
6 cells/injection) or MiaPaCa-2 (2610
6 cells/
injection) cells expressing different OPN constructs were implanted
into the flanks of SCID mice. Tumors were measured every 2–3
days. Tumor volume was calculated by the formula (p x length x
width x height)/6. For metastasis formation, HT1080 (1610
6 cells/
injection) or MiaPaCa-2 (5610
5 cells/injection) cells expressing
different OPN constructs were injected into the tail vein of SCID
mice. After 6 weeks, lung tissue was inflated, fixed, embedded,
sectioned, and stained with hematoxylin and eosin (H&E). Tumor
colonies per lung section were quantified by microscopy.
Histologic Studies
The In Situ Cell Death Detection Kit (Roche, Pleasanton, CA) was
used for apoptosis evaluation on paraffin embedded HT1080 and
frozen MiaPaCa-2 tumor sections according to the manufacturer’s
protocol. Sections were also stained with anti CD31 (Santa Cruz
B i o t e c h n o l o g y ,S a n t aC r u z ,C A ) ,K i 6 7a n t i b o d y( D a k oN o r t h
American, Carpinteria, CA), and CD11b antibody (BD PharMingen,
San Diego,CA).ThehumanHNSCCtissuemicroarraywasgenerated
and stained for OPN and IKK-b as previously described [31].
In Vitro Apoptosis Evaluation
MiaPaCa-2 and HT1080 cells overexpressing different OPN
constructs were plated in 6 cm tissue culture dishes and allowed to
adhere for 24 hrs. The cells were washed, permeabilized with 0.1%
Triton X-100 and fixed in a 4% paraformaldehyde solution
containing 10 ug/mL DAPI (Sigma-Aldrich). Apoptotic nuclei with
condensed chromatin or nuclear fragmentation were assessed
qualitatively using fluorescent microscopy. TUNEL(+) cells were
detected using the In Situ Cell Death Detection Kit (Roche) and
quantified byflowcytometry.Forthe invitrocaspase 3/7 assay, lysates
were combined with a lumogenic substrate containing the DEVD
sequence. Caspase activity was determined by luciferase lumines-
cence per manufacturer instructions (Promega, Madison, WI).
Inhibition of NF-kB
The p65 siRNA (Dharmacon, Lafayette, CO) was used to
inhibit p65 per the manufacturer’s protocol.
Inhibition of FAK
PF573228 (Tocris Bioscience, Ellisville, MO) was added to cell
culture media at a final concentration of 500 nM. Following a 30
minute pre-incubation, media was removed and replaced with
serum-free media containing the inhibitor or vehicle. Cells were
incubated in the anoxia incubator, extracts were collected, and
immunoblotting was performed. Cells were also analyzed for
TUNEL staining by flow cytometry.
Statistics
Statistical analysis was performed using Statview (SAS Institute
Inc, Carey, NY) software. The student T-test and the ANOVA
(analysis of variance) test were use to determine the equality of the
mean between different groups. Results were considered statisti-
cally significant if the p-value was ,0.05.
Results
Expression of Different OPN Splice Variants in Human
Solid Cancers
We used splice form specific primers and qRT-PCR to
determine the presence of OPN-A and B in five tumor cell lines,
24 non-small cell lung cancers (NSCLC) and 30 HNSCC (Fig. S1).
Supplementary Figure S1 shows representative RT-PCR for the
various human solid cancer cell lines and the 4 STS. Most tumors
and cell lines expressed predominantly OPN-A and B but not C.
Based on these data we proceeded to assess OPN-A and B levels
but not C in human NSCLC and HNSCC. Both NSCLC and
HNSCC specimens (Fig. S1) expressed higher levels of OPN-A
and B than normal tissues. OPN-A and B levels tracked well with
total OPN gene expression on gene array analysis (data not
shown). Based on these data, we focused subsequent tumor studies
on OPN-A and B splice forms.
The RGD Region Is Critical for Promoting Tumor Growth
and Metastasis
Two cell lines, which have either undetectable (MiaPaCa-2) or
low basal OPN expression (HT1080), were transfected with
mammalian expression plasmids containing OPN-A, OPN-B,
OPN-A with mutated RGD sequence (OPN-A-RAA) or OPN-B
withdeleted RGDsequence(OPN-B-NoRGD).Apoolofcellsstably
overexpressing the desired OPN construct was selected. Figure 1A
shows overexpression of different OPN constructs in transfected
cells. Note that all OPN isoforms are secreted at similar levels.
Both MiaPaCa-2 and HT1080 cells were injected subcutane-
ously into SCID mice and tumor growth was monitored. Tumors
transfected with WT OPN-A or B grew significantly faster than
the vector control, where as those expressing OPN-A-RAA or
OPN-B-NoRGD grew at a similar rate as the vector control cells
(Fig. 1B). These differences in tumor growth were not due to
changes in cell proliferation because the in vitro proliferation rates
of all cell lines were similar (Fig. 1B, bottom panels).
To test the role the RGD domain in both OPN isoforms during
metastatic spread, the above cells were injected into the tail veins
of SCID mice. After 6 weeks, the lungs were collected and
quantified for metastatic lung colonies. Control cells formed few
colonies (4–5 colonies/field). However, OPN-A and OPN-B
transfected cells formed more numerous and larger metastatic
colonies (16 and 13 colonies/field for HT1080 & 28 colonies/field
for MiaPaCa-2, respectively; Fig. 1C, p,0.001). In contrast,
OPN-A-RAA and OPN-B-NoRGD expressing cells had signifi-
cantly fewer colonies than the WT isoforms. These studies indicate
that OPN promotes metastatic lung colony formation and loss of
the RGD sequence suppresses this phenomenon. Both tumor cell
types used in these assays express avb3 and b1 integrins and can
bind to the RGD sequence (data not shown).
OPN Decreases Apoptosis in Tumors in an RGD
Dependent Manner
Tissue sections from xenografts expressing different OPN
constructs were stained for Ki67 to assess proliferation, CD31
for angiogenesis, CD11b for bone marrow-derived cell infiltration
OPN RGD Promotes Tumor Growth
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were similar between all tumors (data not shown); however, there
was a difference in TUNEL staining among the tumor groups.
While there were numerous TUNEL(+) regions within the control
and OPN-A-RAA tumor sections, these regions were absent in
WT OPN-A expressing tumors (Fig. 2A–B). Quantitation of
TUNEL(+) cells per high power field (HPF) confirmed these
observations (Fig. 2C). Similar results were seen for the OPN-B
isoforms, with fewer TUNEL(+) cells in WT OPN-B as compared
to OPN-B-NoRGD tumors (Fig. 2D). These results indicate that
both OPN isoforms inhibit apoptosis and that this inhibition is
mediated through the RGD.
Tumor-Derived Secreted OPN Can Suppress Apoptosis
but Has No Effect on Cell Adhesion and Migration
Most solid tumors possess regions of reduced oxygen and
nutrients. MiaPaCa-2 cells overexpressing different OPN con-
structs were treated with hypoxia in serum-free media for 48 hrs,
which caused cell apoptosis in all groups. However, there were
fewer apoptotic nuclei (Fig. 3A) and significantly less TUNEL(+)
Figure 1. OPN promotes tumor growth and metastasis through the RGD domain. Overexpression and increased secretion of both OPN
isoforms in MiaPaCa-2 (left) and HT1080 (right) cells stably transfected with OPN-A (A), OPN-B (B), OPN-A-RAA (A-RAA), OPN-B-No RGD (B-NoRGD), or
pcDNA vector control (V) (Pool population) are shown (A). RT-PCR results confirmed expression of the transfected OPN constructs (A, upper panel).
OPN ELISA results confirmed increased OPN secretion in transfected cells (.200 ng/mL) as compared to vector control cells (very low or undetectable
levels). Secretion level was similar for all constructs (A, lower graphs). The RGD region of OPN promotes primary tumor growth in both isoforms (B).
MiaPaCa-2 (left) and HT1080 (right) cells were injected into the flank of SCID mice (n=5). OPN-A and OPN-B expressing tumors were significantly
larger (B, top graphs). MiaPaCa-2 (left) and HT1080 (right) cell lines expressing OPN isoforms were plated in growth media. Similar in vitro growth
rates were observed for all cell lines (B, bottom graphs). The RGD region of OPN mediates lung colony formation in both isoforms (C). MiaPaCa-2
Vector (left), OPN-A (middle) and OPN-A-RAA (right) cells were injected into the tail veins of SCID mice. Lung tissues were harvested 6 weeks later and
stained with H&E. Metastatic lung colonies are indicated with black arrows (C, top panels). Quantification of metastatic lung colony formation in for
MiaPaCa-2 (left) and HT1080 (right) cells overexpressing OPN isoforms is shown (C, bottom graphs). Stars indicate p,0.001.
doi:10.1371/journal.pone.0009633.g001
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PLoS ONE | www.plosone.org 4 March 2010 | Volume 5 | Issue 3 | e9633Figure 2. TUNEL staining in MiaPaCa-2 and HT1080 tumor tissues. MiaPaCa-2 tumors harvested 49 days after rear flank implantation in SCID
mice were frozen and processed for TUNEL staining (A and B). 56magnification is shown (A). 206magnification in areas without large TUNEL(+)
regions is shown (B). Quantification of TUNEL(+) cells in MiaPaCa-2 tumors. Stars indicate p,0.001 (C). Quantification of TUNEL(+) cells in HT1080
tumors harvested at 28 days and processed similarly as MiaPaCa-2 tumors. Star indicates p,0.001 and # indicates p,0.05 (D).
doi:10.1371/journal.pone.0009633.g002
Figure 3. OPN prevention of apoptosis requires the RGD domain. MiaPaCa-2 cells transfected with the vector control (V), OPN-A (A) or OPN-
A-RAA (A-RAA) were treated with hypoxia in serum free media for 48 hours and stained with DAPI. Note that more apoptotic nuclei are present in
MiaPaCa-2 vector control and RAA compared to OPN-A overexpression (A). Histograms showing TUNEL(+) cells by flow cytometry after 48 hours of
hypoxia in serum free media (B). Quantification of the percentage of TUNEL-positive cells in MiaPaCa-2 cells transfected with the indicated OPN
constructs from flow cytometry, p,0.02 (C). Measurement of caspase 3/7 activity in MiaPaCa-2 vector control cells (V) treated with condition media
harvested from vector (V+V), OPN-A (V+A) and OPN-A-RAA (V+RAA) secreting cells is shown. Caspase 3/7 activity for MiaPaCa-2 OPN-A overexpressing
cells incubated in conditioned media from OPN-A secreting cells (A+A) is also indicated. Stars indicate p,0.0001 compared to V+V group (D).
doi:10.1371/journal.pone.0009633.g003
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(Fig. 3B–C). Mutation of the RGD sequence to RAA prevented
OPN-mediated protection of apoptosis from hypoxia and serum
starvation (Fig. 3A–C). Similarly, OPN-B overexpression signifi-
cantly reduced apoptosis under hypoxia and serum starvation in
HT1080 cells, and deletion of the RGD sequence reversed this
effect (Fig. S2). The conditioned media from WT OPN-A
secreting cells, but not OPN-RAA cells, was able to reduce cell
death from hypoxia and serum starvation when applied to vector
control cells, assessed by Caspase 3/7 activity assay (Fig. 3D).
These data indicate that OPN-A and B isoforms inhibit apoptosis
induced by hypoxia and serum starvation through the RGD
domain.
To determine the effect of RGD domain on other cellular
attributes that may enhance tumor growth or metastasis, we
evaluated the effect of OPN overexpression, either WT or with the
RGD mutated on cell-cell adhesion (serum free media) and
anchorage independent growth (soft agar assay). Neither OPN
overexpression or RGD mutation significantly influenced cell-cell
adhesion or soft agar growth (assessed for both colony number and
size) (Fig. 4A–B). Similarly, neither overexpression of OPN-A or B
nor treatment of recombinant OPN isoforms increased cell
migration or invasion in the tested cell lines in serum free media
(data not shown). Scratch assays also showed that mutation of the
RGD did not affect cell migration in serum free media (Fig. 4C).
These studies confirm that the main function of the RGD domain
is to protect cell from apoptosis.
The RGD Domain of OPN Mediates Apoptosis Partially via
NF-kB Activation
NF-kB activation protects cells from apoptosis and OPN can
promote NF-kB activation. Hence, we evaluated NF-kB activity in
MiaPaCa-2 cells expressing different OPN constructs. Overex-
pression of WT OPN isoforms resulted in significant increase of
NF-kB-dependent luciferase activity and either mutation (OPN-A-
RAA) or deletion (OPN-B-NoRGD) of the RGD domain
eliminated this effect, although the absolute effect was modest
(Fig. 5A). We also assessed protein expression of selective NF-kB
endogenous targets. OPN-A or OPN-B overexpressing cells had
higher Bcl-2 and XIAP protein levels than vector control, OPN-A-
RAA and OPN-B-NoRGD cells (Fig. 5B). These results indicate
that OPN activates NF-kB under stressed conditions, and the
RGD domain of OPN mediates this effect.
MiaPaCa-2 cells overexpressing different OPN constructs
were transiently transfected with a p65 siRNA oligo to inhibit
NF-kB activation. Transfection with this oligo had minimal
effect on apoptosis in control, OPN-A-RAA or OPN-B-NoRGD
cells under stressed conditions (Fig. 5C). In contrast, inhibition
Figure 4. Overexpression of different OPN isoforms or their mutants does not affect cell-cell adhesion, soft agar colony formation
or migration in serum free media. A cell-cell adhesion assay was performed with FaDu HNC cells (5610
4) expressing the indicated OPN
constructs. Adherent cells were quantified by luciferase activity (A). Soft agar colony formation of MiaPaCa-2 cells overexpressing different OPN
constructs was quantified by number of colonies (left graph) and the average colony area (right graph) (B). A Scratch assay was performed with
MiaPaCa-2 cells overexpressing different OPN constructs exhibiting similar cell migration. Picture was taken at 406total magnification (C).
doi:10.1371/journal.pone.0009633.g004
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overexpressing either WT OPN-A or B compared to the
scrambled control (13.8% vs. 7.5% and 13.6% vs. 6.6%, res-
pectively, Fig. 5C). However, the level of apoptosis with NF-kB
inhibition in WT OPN cells was still less than that observed in
vector control or OPN-A-RAA cells, suggesting that NF-kB
activation alone may only be partially responsible for OPN-
mediated cell survival.
IkB Kinase b (IKK-b) activates NF-kB through phosphoryla-
tion and degradation of IkB-a. High IKK-b correlates with
increased NF-kB activity and vice-versa. Although we cannot
directly measure NF-kB activity in archival human cancer tissues,
we can stain them for IKK-b as a surrogate marker for NF-kB
activity. We stained a tissue microarray containing 89 HNSCCs
for OPN and IKK-b. We found a significant correlation between
OPN and IKK-b expression (p=0.025, Fisher exact test).
Concordant expression between the two markers was noted in
70 tumors and discordant expression in 19 tumors (data not
shown). These results suggest that NF-kB activity and OPN
expression are strongly related in human tumors.
The RGD Segment of OPN Also Mediates Apoptosis
Partially via FAK Activation
Since the RGD sequence binds to av integrins, which are known
to signal through the FAK pathway, and OPN activates FAK in
cell migration, we also evaluated the effect of RGD mutation on
the activation of this pathway. MiaPaCa-2 cells expressing
different OPN constructs were subjected to hypoxia and serum
starvation. Prior to hypoxia and serum starvation, pFAK levels
were elevated in all cells. After 30–60 min of hypoxia and serum
starvation, FAK phosphorylation decreased in the vector control
and OPN-A-RAA cells, whereas they remained high in WT OPN-
A expressing cells (Fig. 6A). These results indicate that the RGD
domain within OPN is important for sustaining FAK activation
under stress.
To suppress FAK activation, MiaPaCa-2 cells expressing OPN
isoforms were pre-treated with the FAK-specific inhibitor
PF573228 (500 nM) or the vehicle for 30 min followed by
exposure to hypoxia. As shown in Figure 6B, pretreatment with
the FAK inhibitor completely blocked FAK phosphorylation at the
tyrosine 397 residue in all cells.
Figure 5. The RGD domain of OPN enhances NF-kB activation under stress conditions and partially protects cells from apoptosis.
Quantification of NF-kB-dependent luciferase activity in MiaPaCa-2 cells overexpressing the indicated OPN constructs cultured under hypoxia and
serum starvation. Stars indicate p,0.05 (A). XIAP and Bcl-2 immunoblots of MiaPaCa-2 cells overexpressing the indicated hOPN WT and hOPN
mutants are shown. b-actin blot confirms equal protein loading (B, left blots). Quantitation of band intensities is shown (B, right graph). Inhibition of
p65 expression reduces OPN-mediated cell survival (C). RT-PCR confirmation of similar p65 knockdown with p65-specific siRNA (grey bars) in
MiaPaCa-2 cells stably transfected with the indicated constructs. Data was normalized to scramble control (black bars) (C, left graph). Flow cytometry
quantification of TUNEL-positive staining MiaPaCa-2 cells, stably transfected with the indicated constructs and subjected to either p65 knockdowno r
scramble control, after 48 hours hypoxia in serum free media was performed. Stars indicate p,0.05. (C, right graph).
doi:10.1371/journal.pone.0009633.g005
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enhance cell migration or invasion in evaluated cell lines. To
determine if FAK phosphorylation is required for OPN-mediated
cell survival under hypoxia and serum-starvation, MiaPaCa-2 cells
expressing different OPN constructs were treated with PF573228
under these conditions. Addition of FAK inhibitor led to a small
increase in TUNEL(+) cells under control conditions, suggesting a
modest cytotoxic effect of the drug alone (Fig. 6C, N+Vehicle vs
N+Inhibitor). However, under serum starved/hypoxia treatment,
the addition of PF573228 strongly increased the percentage of
TUNEL(+) cells for OPN-A expressing cells compared to vehicle
(Fig. 6C). In contrast, the percentage of TUNEL(+) cells was only
slightly elevated in control and OPN-A-RAA cells treated with
PF573228. Taken together, these data suggest that OPN activates
FAK through an RGD-dependent mechanism, which protects
cells from apoptosis during hypoxia and serum starvation.
Since AKT has been shown to be activated by OPN and is a
well-known survival factor, we also assessed AKT phosphorylation
for cells transfected with different constructs under different
conditions. There was no difference in the level of either total or
phospho-AKT for cells expressing different constructs under
hypoxia and serum starvation (Fig. S3).
Discussion
The effect of modulating OPN expression has been studied in
many cancer types. Overexpression of OPN increased growth
[32,33], whereas inhibition of OPN reduced growth in multiple
tumor types [32,34,35]. These gain and loss of function studies
indicate that OPN is involved in modulating tumor growth;
however, the importance of the RGD domain within OPN in
different OPN isoforms has not been rigorously characterized
genetically. Here, we systematically define the effect of the RGD
domain on tumor progression by either mutation or deletion in 2
different OPN isoforms and express them in different cell types.
Overexpression of OPN isoforms containing the WT RGD, but
Figure 6. The RGD domain of OPN activates FAK and partially protects cells from apoptosis under stress conditions. OPN
overexpression sustains FAK activation during stress through the RGD domain. Immunoblot analysis of phospho-FAK and total FAK in MiaPaCa-2 cells
stably transfected with constructs for OPN-A (A), OPN-A-RAA (RAA), or vector control (V), treated with hypoxia in serum free media for the indicated
times (minutes). b-actin blot shows equal loading (A). Addition of PF573228 (FAK inhibitor) completely inhibits FAK phosphorylation. Phospho-FAK
and total FAK immunoblotting in MiaPaCa-2 cells (Vector, OPN-A, OPN-A-RAA) pre-treated with PF573228 (500 nM) or DMSO for 30 minutes followed
by exposure to hypoxia for an additional 30 minutes. b-actin blot shows equal loading (B). Inhibition of FAK activation reduced OPN-mediated cell
survival under stress. MiaPaCa-2 cells (Vector, OPN-A, OPN-A-RAA) were pre-treated with either vehicle or PF573228 (500 nM) for 30 minutes and then
exposed to either normoxia or hypoxia in serum free media for 40 hours. TUNEL(+) cells were quantified by flow cytometry.
doi:10.1371/journal.pone.0009633.g006
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both local tumor growth and metastatic lung colony formation. In
fact, the RGD domain was essential for tumor growth promotion
in our xenograft models.
Interestingly, our mouse tumor data indicate that the RGD
domain of OPN mediates tumor growth and metastasis mainly
through decreased apoptosis. Similar findings were noted for in
vitro assays. Overexpression of WT OPN but not mutant RGD
protects cells from apoptosis triggered by hypoxia and serum
starvation. However, such overexpression did not affect cell
adhesion, migration or anchorage independent growth.
Although our results, which show that the major function of the
RGD domain is to protect cancer cells from stress-induced
apoptosis are different from prior studies using recombinant
bacterially derived OPN [36,37,38,39], they are consistent with
studies which used human-derived soluble OPN or antibodies that
block autocrine OPN function [40,41,42,43]. OPN deficient mice
have higher TUNEL staining and less papilloma development
when treated with carcinogen compared to WT mice [44].
Reducing OPN expression by RNA interference leads to increased
TUNEL staining and caspase-3 activity [45]. Mechanistically,
OPN has been shown to counteract the pro-apoptotic effect of
serum starvation in two-dimensional [40] and three-dimensional
cultures [41], through the RGD domain. Interestingly, intracel-
lular cleavage of OPN by caspase 3 and 8 can enhance apoptotic
cell death under hypoxia and reoxygenation, and one of the
cleavage sites is located immediately adjacent to the RGD [43].
Collectively, these reports suggest that OPN isoforms promote
both tumor growth and metastasis through the same mechanism,
which is to protect cells from apoptosis under the stresses
encountered within the tumor microenvironment, notably through
the RGD domain. Since the RGD domain of OPN interacts with
multiple cellular receptors including the av family of integrins,
strategies that block such an interaction may be beneficial in the
treatment of solid tumors. For example, CNTO 95, a fully human
anti-av integrin monoclonal antibody, has been shown to have
antitumor activity by itself [46,47] and can enhance the
therapeutic efficacy of fractionated radiation therapy in xenografts
via increasing apoptosis [48]. Several clinical studies are ongoing
to test the toxicity and efficacy of such anti-integrin antibody either
alone or in combination with conventional therapy in solid
tumors.
OPN is well known in the literature as a survival factor that
mediates cell apoptosis under certain pathological stresses. It has
been shown to inhibit cell apoptosis in several systems including
cardiac myocytes from ischemia/reperfusion injury [49], endo-
thelial cells from growth factor deprivation [40], intestinal
epithelial cells from inflammation [50] and immune cells from
certain stresses [51,52,53]. However, the detailed pathways and
mechanisms by which OPN mediates its anti-apoptotic effect can
be different for various cell types and stressors. NF-kB activation is
believed to be a major effector of OPN-mediated cell survival.
OPN protects cells from denatured collagen II, by increasing p50
and p65 DNA binding [54]. Soluble OPN protects lymphocytes
from apoptosis, by activating NF-kB [55]. Inhibition of OPN leads
to increased cell death, increased TUNEL staining, decreased NF-
kB binding and increased levels of the inhibitor IkB-a [34].
Furthermore, interaction between the RGD domain of OPN and
integrin avb3 receptors leads to NF-kB activation and cell survival
[56]. Our data confirm that overexpression of OPN isoforms
containing the RGD domain lead to enhanced NF-kB activation,
while isoforms lacking the RGD domain do not. Such activation
does occur in actual human HNSCC as suggested by co-
localization between OPN and IKK-b, a target of NF-kB pathway
[57,58]. Inhibition of NF-kB activity partially suppresses OPN-
mediated protection from apoptosis in hypoxic/serum-starved
cells. Our data therefore indicates that NF-kB activation is at least
partially responsible for OPN mediated survival via the RGD
domain.
FAK activation promotes cell proliferation, survival and
migration [59]. FAK is tyrosine phosphorylated in response to
ligation of b1 or b3 integrins [60]. Since the RGD domain of OPN
binds to avb3 and avb1 integrins, FAK activation was measured in
cell lines overexpressing OPN isoforms. WT OPN isoforms, but
not those lacking the RGD domain, retained FAK phosphoryla-
tion in hypoxic/serum-starved cells. These results are similar to
those previously published [61,62]. Moreoever, inhibition of FAK
phosphorylation with a specific inhibitor resulted in a marked
enhancement of apoptosis seen only in WT OPN expressing cells
but not those with mutated OPN-A isoform. Our data indicates
that FAK is another survival pathway that is regulated by the
RGD domain of OPN. However, not all survival pathways are
engaged by the RGD domain of OPN as AKT is one such
pathway (Figure S3) [63], indicating that RGD activation of
survival pathways under hypoxia and serum starvation is a specific
process.
Little is known about the function of different OPN isoforms in
human tumors. The first study which systematically evaluated the
expression and function of different OPN splice forms in breast
cancer indicated that OPN-C was selectively expressed in invasive
breast cancer and more likely to support anchorage independent
tumor growth than OPN-A in a breast cancer cell line. However,
subsequent studies have found that OPN-A and B are more likely
to be expressed in hepatocellular carcinoma and lung cancer than
OPN-C [64,65]. Overexpression of OPN-A and to some extent
OPN-B in NSCLC cell lines resulted in increased VEGF secretion
and bovine capillary tube length formation, whereas the reverse
was noted for OPN-C overexpression [64]. Similarly, OPN-A and
B induced Hep3B cell migration, while OPN-C had no significant
effects [65]. These data are consistent with our findings, indicating
that OPN-A and B are the predominant isoforms found in solid
tumors and that both can enhance tumor growth and metastasis at
an equivalent level.
In summary, expression of both OPN-A and OPN-B isoforms
are commonly observed in NSCLC and HNSCC. Forced
overexpression of either isoform promotes tumor growth and
metastasis, and the RGD domain within OPN is required for the
effect to occur. OPN overexpressing cells have reduced apoptotic
cell death both in vivo and in vitro. OPN, acting through the RGD
domain, protects the cells by activating NF-kB and FAK but not
AKT. These data indicate that the predominant mechanism, by
which OPN promotes tumor growth and metastasis through the
RGD domain, is enhancement of survival in the tumor
microenvironment. Therefore inhibitors directed against OPN
should target multiple isoforms and should inhibit cell survival
mechanisms that involve the RGD domain, FAK phosphorylation
and NF-kB activation.
Supporting Information
Figure S1 Expression of OPN-A and OPN-B isoforms in human
cancer cell lines and primary human tumors. Poly-A RNA was
extracted from human STS including giant cell tumor (GCT),
pigmented villonodular synovial tumor (PVNS) and leiomyosar-
coma (LMS) samples and amplified by RT-PCR using the
universal OPN primer set (left) (A). HT1080 RNA was used as a
positive control for OPN-A and OPN-B expression (A, right lane).
RNAs extracted from the indicated human cancer cell lines were
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PLoS ONE | www.plosone.org 9 March 2010 | Volume 5 | Issue 3 | e9633subjected to RT-PCR and resulting cDNAs were amplified using
the universal OPN primer set (right panel) (A). pCDNA -OPN-A
and B plasmids were used as positive controls for the amplification
of the indicated OPN isoforms. NS indicates non-specific band (A,
right panel). The fold increase of NSCLC OPN-A (stripe) and
OPN-B (black) mRNA expression relative to 18S in human
NSCLC specimens (LCC) and Normal Lung Tissue (NOR)( B) or
in human HNSCC normalized to HN99 (one HNSCC sample)
(C), based on qRT-PCR assay is shown. Tumors were arranged by
overall total OPN mRNA expression based on gene expression
data with increasing expression from left to right (B and C).
Found at: doi:10.1371/journal.pone.0009633.s001 (0.42 MB TIF)
Figure S2 Percentage of TUNEL(+) cells in HT1080 cells
transfected with different OPN constructs under hypoxia in serum
free media.
Found at: doi:10.1371/journal.pone.0009633.s002 (0.10 MB TIF)
Figure S3 Immunoblot showing total AKT and pAKT
expression for MiaPaCa-2 cells expressing different OPN
constructs under normoxia or 1 hour of hypoxia in serum free
media. b-actin bands confirmed equal loading.
Found at: doi:10.1371/journal.pone.0009633.s003 (0.17 MB TIF)
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